Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a placebo and somatropin. Somatropin is a recombinant form of human growth hormone (hGH) used to treat various conditions related to growth hormone deficiency, including pediatric and adult growth failure, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, chronic kidney disease-related growth failure, children born small for gestational age without catch-up growth, HIV-associated wasting or cachexia in adults, and short bowel syndrome in adults[1][2][3][4][5]. Somatropin acts by binding to the human growth hormone receptor (GHR), activating intracellular signaling pathways that promote linear bone growth in children and regulate metabolism in both children and adults[5]. The placebo component has no pharmacological activity but may be used as a control in clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + somatropin.